Inverness Medical Innovations Announces Third Quarter 20...(measures used by other companies. (b)...),Health

(b) Amortization expense of $185.3 million and $155.1 million in the first nine months of 2009 and 2008 GAAP results, respectively, including $30.5 million and $34.2 million charged to cost of sales, $3.2 million and $2.8 million charged to research and development and $150.9 million and $117.4 million charged to selling, general and administrative, in the respective periods, with $0.7 million charged through equity earnings of unconsolidated entities, net of tax during each of the respective periods.

(c) Restructuring charges associated with the decision to close facilities of $16.5 million and $45.7 million in the first nine months of 2009 and 2008 GAAP results, respectively. The $16.5 million charge for the nine months ended September 30, 2009 included $6.1 million charged to cost of sales, $0.9 million charged to research and development, $5.1 million charged to selling, general and administrative, $0.5 million charged to interest expense and $3.9 million charged through equity earnings of unconsolidated entities, net of tax. The $45.7 million charge for the nine months ended September 30, 2008 included $16.4 million charged to cost of sales, $6.9 million charged to research and development, $9.6 million charged to selling, general and administrative, $6.9 million charged to interest expense and $6.0 million charged through equity earnings of unconsolidated entities, net of tax. These charges have been excluded from net income or loss because they have a significant impact on results yet do not occur on a consistent or regular basis in the Company's business.

(d) Compensation costs of $20.3 million and $19.7 million associated with stock-based compensation expense in the first nine months of 2009 and 2008 GAAP results, respectively, including $1.5 million and $1.0 million charged to cost of sales, $3.7 million and $3.4 million charged to research and development and $15.1 million and $1
'/>"/>